<DOC>
	<DOCNO>NCT00003368</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Irinotecan may effective treat patient abnormal liver kidney function receive radiation therapy . PURPOSE : Phase I trial study effectiveness irinotecan treat patient solid tumor lymphoma abnormal liver kidney function previous radiation therapy pelvis .</brief_summary>
	<brief_title>Irinotecan Treating Patients With Solid Tumors Lymphoma Who Have Abnormal Liver Kidney Function Who Have Received Radiation Therapy Pelvis</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose irinotecan patient solid tumor lymphoma liver renal dysfunction prior pelvic radiation . II . Characterize pharmacokinetics irinotecan patient . OUTLINE : This dose escalation study . Patients stratify accord prior pelvic radiation therapy ( yes v ) . Patients prior pelvic radiation stratify accord AST , bilirubin , creatinine level . Patients receive irinotecan IV 90 minute every 3 week total 2 course . After patient reevaluate , treatment may continue absence disease progression unacceptable toxicity . Cohorts 3 6 patient receive escalate dos irinotecan . Dose escalation proceeds within stratum maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 75 patient accrue study rate 2-3 patient per month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven solid tumor lymphoma refractory standard therapy standard therapy exist Brain metastasis allow follow criterion meet : Asymptomatic Received prior therapy brain metastasis Stable least 2 month No concurrent steroid therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : CALGB 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic Renal : Albumin least 2.5 g/dL Prothrombin time le 1.6 For patient without prior pelvic radiotherapy : AST least 3 time upper limit normal ( ULN ) OR Bilirubin 1.0 7.0 mg/dL AST OR Creatinine 1.6 5.0 mg/dL For patient prior pelvic radiotherapy : AST le 3 time ULN AND Bilirubin less 1.0 mg/dL AND Creatinine less 1.6 mg/dL Other : Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent colony stimulate factor Chemotherapy : At least 4 week since prior chemotherapy ( least 6 week since melphalan mitomycin ) At least 3 month since suramin No prior nitrosoureas irinotecan Endocrine therapy : No concurrent steroid ( except antiemetic chemotherapy ) Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 4 week since major surgery Other : No concurrent medication know affect hepatic renal function ( e.g. , antiseizure medication nonsteroidal antiinflammatory drug )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>